| |
| |
|
| Insider
Information: |
Bailey Jeffrey Allen |
| Relationship: |
Director |
| City: |
Bristol |
| State: |
TN |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
138,447 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$4,408,045 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
138,447 |
|
|
| Total
Value |
$4,408,045 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
4
|
1
|
|
Stock
price went up :
|
4
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
4.0
|
-1.0
|
| Percentage
Gain/Loss : |
 25.2%
|
 -13.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
King Pharmaceuticals Inc |
KG |
Chief Commercial Officer |
2011-01-31 |
0 |
2010-08-30 |
0 |
Premium* |
|
|
Landauer Inc |
LDR |
Director |
2017-10-19 |
0 |
2015-04-17 |
0 |
Premium* |
|
|
Lantheus Holdings, Inc. |
LNTH |
CEO and President, Dir... |
2015-08-31 |
60,933 |
|
0 |
Premium* |
|
|
Aileron Therapeutics Inc |
ALRN |
Director |
2019-11-15 |
74,894 |
2019-11-12 |
0 |
Premium* |
|
|
Biodelivery Sciences Internation... |
BDSI |
Chief Executive Office... |
2022-03-22 |
0 |
2020-08-07 |
0 |
Premium* |
|
|
H&Q Healthcare Investors |
HQH |
Director |
2020-09-23 |
490 |
2020-09-23 |
0 |
Premium* |
|
|
Tekla Life Sciences Investors |
HQL |
Director |
2020-09-22 |
580 |
2020-09-22 |
0 |
Premium* |
|
|
Tekla World Healthcare Fund |
THW |
Director |
2021-04-06 |
980 |
2020-09-23 |
0 |
Premium* |
|
|
Tekla Healthcare Opportunities F... |
THQ |
Director |
2020-09-23 |
570 |
2020-09-23 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BDSI |
Biodelivery Sciences Inte... |
Chief Executive Officer |
• • – |
2022-03-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(105,133) |
0 |
0 |
- |
|
| BDSI |
Biodelivery Sciences Inte... |
Chief Executive Officer |
• • – |
2022-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,333 |
105,133 |
0 |
- |
|
| BDSI |
Biodelivery Sciences Inte... |
Chief Executive Officer |
• • – |
2021-11-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
53,333 |
99,800 |
0 |
- |
|
| BDSI |
Biodelivery Sciences Inte... |
Chief Executive Officer |
• • – |
2021-08-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,567 |
46,467 |
0 |
- |
|
| THW |
Tekla World Healthcare Fu... |
Director |
– • – |
2021-04-06 |
4 |
OE |
$14.26 |
$3,494 |
D/D |
245 |
980 |
0 |
- |
|
| BDSI |
Biodelivery Sciences Inte... |
Chief Executive Officer |
• • – |
2021-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,333 |
40,900 |
0 |
- |
|
| BDSI |
Biodelivery Sciences Inte... |
Chief Executive Officer |
• • – |
2020-12-15 |
4 |
S |
$4.35 |
$43,500 |
D/D |
(10,000) |
35,567 |
0 |
% |
|
| BDSI |
Biodelivery Sciences Inte... |
Chief Executive Officer |
• • – |
2020-11-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
40,000 |
45,567 |
0 |
- |
|
| THQ |
Tekla Healthcare Opportun... |
Director |
– • – |
2020-09-23 |
4 |
B |
$17.68 |
$10,078 |
D/D |
570 |
570 |
2.39 |
% |
|
| THW |
Tekla World Healthcare Fu... |
Director |
– • – |
2020-09-23 |
4 |
B |
$14.18 |
$10,068 |
D/D |
710 |
710 |
2.39 |
% |
|
| HQH |
H&Q Healthcare Investors |
Director |
– • – |
2020-09-23 |
4 |
B |
$20.39 |
$9,991 |
D/D |
490 |
490 |
2.39 |
% |
|
| HQL |
Tekla Life Sciences Inves... |
Director |
– • – |
2020-09-22 |
4 |
B |
$17.28 |
$10,022 |
D/D |
580 |
580 |
2.39 |
% |
|
| BDSI |
Biodelivery Sciences Inte... |
Chief Executive Officer |
• • – |
2020-08-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,567 |
5,567 |
0 |
- |
|
| ALRN |
Aileron Therapeutics Inc |
Director |
– • – |
2019-11-15 |
4 |
B |
$0.51 |
$19,962 |
D/D |
39,142 |
74,894 |
2.39 |
- |
|
| ALRN |
Aileron Therapeutics Inc |
Director |
– • – |
2019-11-14 |
4 |
B |
$0.51 |
$8,088 |
D/D |
15,858 |
35,752 |
2.39 |
- |
|
| ALRN |
Aileron Therapeutics Inc |
Director |
– • – |
2019-11-12 |
4 |
B |
$0.53 |
$10,544 |
D/D |
19,894 |
19,894 |
2.39 |
- |
|
| LDR |
Landauer Inc |
Director |
– • – |
2017-10-19 |
4 |
D |
$67.25 |
$601,417 |
D/D |
(8,943) |
0 |
0 |
- |
|
| LDR |
Landauer Inc |
Director |
– • – |
2017-02-16 |
4 |
A |
$50.90 |
$115,034 |
D/D |
2,260 |
8,943 |
0 |
- |
|
| LDR |
Landauer Inc |
Director |
– • – |
2016-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,959 |
6,683 |
0 |
- |
|
| LNTH |
Lantheus Holdings, Inc. |
CEO and President |
• • – |
2015-08-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(181,494) |
60,933 |
0 |
- |
|
| LNTH |
Lantheus Holdings, Inc. |
CEO and President |
• • – |
2015-07-17 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
242,427 |
0 |
- |
|
| LNTH |
Lantheus Holdings, Inc. |
CEO and President |
• • – |
2015-07-17 |
4/A |
D |
$7.13 |
$92,833 |
D/D |
(13,020) |
229,407 |
0 |
- |
|
| LNTH |
Lantheus Holdings, Inc. |
CEO and PresidentOfficer |
• • – |
2015-06-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
202,427 |
|
- |
|
| LDR |
Landauer Inc |
Director |
– • – |
2015-04-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,724 |
2,724 |
0 |
- |
|
| KG |
King Pharmaceuticals Inc |
Chief Commercial Officer |
• – – |
2011-01-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(40,000) |
0 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
